OPRK1 and Pruritus: A recent meta-analysis reviewed multiple Japanese clinical trials on the clinical efficacy and safety of nalfurafine, a kappa-opioid receptor (KOR) agonist with central action, in the treatment of pruritus from various causes, particularly uremic pruritus in dialysis patients and hepatic pruritus in individuals with chronic liver disease [32], (Figure 9).